BACKGROUND: The use of highly active antiretroviral therapy (HAART) results in multiple side effects that may jeopardize the life of the patient being treated with antiretroviral drugs. In resource-poor settings it is difficult to definitively diagnose lactic acidosis by laboratory measurement of lactate. Point-of-care (POC) devices are helpful in the measurement of lactate levels and have been validated in the intensive care unit setting, but not in a busy outpatient clinic. The objective of this study was to assess the sensitivity and specificity of the Accutrend lactate meter in the diagnosis of hyperlactatemia/lactic acidosis in patients on nucleoside reverse transcriptase inhibitor (NRTI)-containing regimens (stavudine). DESIGN AND METHODS: This was a cross-sectional study of 120 patients on HAART (lamivudine, stavudine, efavirenz, or nevirapine) with symptoms of/or recovering from hyperlactatemia/lactic acidosis. Simultaneous testing of the same blood sample was undertaken on the Accutrend handheld lactate analyzer and a reference instrument (Beckman CX7 Synchron machine). A venous lactate level <2.2mmol/l was considered as normal. RESULTS: The mean lactate value obtained from the Accutrend meter was 2.89mmol/l and from the reference instrument was 2.78mmol/l. The standard deviation for Accutrend meter was 1.14mmol/l vs.1.42mmol/l for the Beckman instrument. The sensitivity obtained for the Accutrend meter was 95.9% (95% CI 87.7-98.9%) and the specificity 63.8% (95% CI 48.5-76.9%). The positive predictive value was 80.5% (95% CI 70.3-87.9%) and the negative predictive value was 90.9% (95% CI 74.5-97.6%). CONCLUSIONS: The Accutrend lactate meter is an appropriate device for screening patients on HAART with symptoms of hyperlactatemia/lactic acidosis. The use of this device decreases analytic and intervention time, preventing further morbidity and mortality in patients on an NRTI (stavudine)-based regimen.
BACKGROUND: The use of highly active antiretroviral therapy (HAART) results in multiple side effects that may jeopardize the life of the patient being treated with antiretroviral drugs. In resource-poor settings it is difficult to definitively diagnose lactic acidosis by laboratory measurement of lactate. Point-of-care (POC) devices are helpful in the measurement of lactate levels and have been validated in the intensive care unit setting, but not in a busy outpatient clinic. The objective of this study was to assess the sensitivity and specificity of the Accutrend lactate meter in the diagnosis of hyperlactatemia/lactic acidosis in patients on nucleoside reverse transcriptase inhibitor (NRTI)-containing regimens (stavudine). DESIGN AND METHODS: This was a cross-sectional study of 120 patients on HAART (lamivudine, stavudine, efavirenz, or nevirapine) with symptoms of/or recovering from hyperlactatemia/lactic acidosis. Simultaneous testing of the same blood sample was undertaken on the Accutrend handheld lactate analyzer and a reference instrument (Beckman CX7 Synchron machine). A venous lactate level <2.2mmol/l was considered as normal. RESULTS: The mean lactate value obtained from the Accutrend meter was 2.89mmol/l and from the reference instrument was 2.78mmol/l. The standard deviation for Accutrend meter was 1.14mmol/l vs.1.42mmol/l for the Beckman instrument. The sensitivity obtained for the Accutrend meter was 95.9% (95% CI 87.7-98.9%) and the specificity 63.8% (95% CI 48.5-76.9%). The positive predictive value was 80.5% (95% CI 70.3-87.9%) and the negative predictive value was 90.9% (95% CI 74.5-97.6%). CONCLUSIONS: The Accutrend lactate meter is an appropriate device for screening patients on HAART with symptoms of hyperlactatemia/lactic acidosis. The use of this device decreases analytic and intervention time, preventing further morbidity and mortality in patients on an NRTI (stavudine)-based regimen.
Authors: Richard Ssekitoleko; Relana Pinkerton; Rose Muhindo; Sanjay Bhagani; Christopher C Moore Journal: Am J Trop Med Hyg Date: 2011-10 Impact factor: 2.345
Authors: Marilyn J Crain; Paige L Williams; Ray Griner; Katherine Tassiopoulos; Jennifer S Read; Lynne M Mofenson; Kenneth C Rich Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: M Waiswa; B B Byarugaba; P Ocama; H Mayanja-Kizza; E Seremba; S Ganguli; M Crowther; R Colebunders Journal: Afr Health Sci Date: 2012-09 Impact factor: 0.927
Authors: Charlotte Schutz; Andrew Boulle; Dave Stead; Kevin Rebe; Meg Osler; Graeme Meintjes Journal: AIDS Res Ther Date: 2010-05-26 Impact factor: 2.250
Authors: Sérgio Monteiro de Almeida; Jennifer Marquie-Beck; Archana Bhatt; Scott Letendre; Allen McCutchan; Ron Ellis Journal: Arq Neuropsiquiatr Date: 2014-07 Impact factor: 1.420
Authors: Filipe Dinato de Lima; Ana Luiza Matias Correia; Denilson da Silva Teixeira; Domingos Vasco da Silva Neto; Ítalo Sávio Gonçalves Fernandes; Mário Boratto Xavier Viana; Mateus Petitto; Rodney Antônio da Silva Sampaio; Sandro Nobre Chaves; Simone Teixeira Alves; Renata Aparecida Elias Dantas; Márcio Rabelo Mota Journal: Int J Gen Med Date: 2015-08-13
Authors: Rodrigo W A Souza; Warlen P Piedade; Luana C Soares; Paula A T Souza; Andreo F Aguiar; Ivan J Vechetti-Júnior; Dijon H S Campos; Ana A H Fernandes; Katashi Okoshi; Robson F Carvalho; Antonio C Cicogna; Maeli Dal-Pai-Silva Journal: PLoS One Date: 2014-10-17 Impact factor: 3.240